{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:50:42Z","timestamp":1765079442857,"version":"3.46.0"},"reference-count":45,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,4,17]]},"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      A single dose or short course of primaquine given to people infected with malaria may reduce transmission of\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      through its effects on gametocytes. Primaquine is also known to cause haemolysis in people with variants of glucose-6-phosphate dehydrogenase (G6PD) deficiency. The objective of this systematic review was to assess the risk of adverse effects in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than 7\u2005days).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will search the following databases: Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS. Prospective cohort studies, randomised and quasi-randomised trials that evaluated 8AQs for whatever reason in adults or children with a known G6PD deficiency will be included. Two authors will independently assess each study for eligibility, risk of bias and extract data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This systematic review will be published in a peer-reviewed journal. Brief reports of the review findings will be disseminated directly to the appropriate audiences and the WHO Technical Expert Group in Malaria Chemotherapy. As no primary data collection will be undertaken, no additional formal ethical assessment and informed consent are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol registration in PROSPERO<\/jats:title>\n                    <jats:p>The protocol is registered with PROSPERO, registration number CRD42013006518.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-004664","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T21:21:51Z","timestamp":1400188911000},"page":"e004664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies"],"prefix":"10.1136","volume":"4","author":[{"given":"Olalekan A","family":"Uthman","sequence":"first","affiliation":[{"name":"Division of Health Sciences, Warwick\u2014Centre for Applied Health Research and Delivery (WCAHRD), Warwick Medical School, University of Warwick, Coventry, UK"},{"name":"Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Saunders","sequence":"additional","affiliation":[{"name":"Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Graves","sequence":"additional","affiliation":[{"name":"School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellen","family":"Gelband","sequence":"additional","affiliation":[{"name":"Center for Disease Dynamics, Economics & Policy, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick\u2014Centre for Applied Health Research and Delivery (WCAHRD), Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Garner","sequence":"additional","affiliation":[{"name":"Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"key":"2025120618272657000_4.5.e004664.1","unstructured":"WHO. Guidelines for the treatment of malaria. 2nd edn. Geneva, Switzerland: World Health Organization, 2010."},{"key":"2025120618272657000_4.5.e004664.2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05566-11"},{"key":"2025120618272657000_4.5.e004664.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.08.011"},{"key":"2025120618272657000_4.5.e004664.4","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(94)90305-0"},{"key":"2025120618272657000_4.5.e004664.5","doi-asserted-by":"publisher","DOI":"10.1086\/324085"},{"key":"2025120618272657000_4.5.e004664.6","unstructured":"WHO. WHO Evidence Review Group: the safety and effectiveness os single dose primaquine as a P. falciparium gametoctyocide . Meeting Report. Geneva, Switzerland: World Health Organization, 2012."},{"key":"2025120618272657000_4.5.e004664.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(03)00005-9"},{"key":"2025120618272657000_4.5.e004664.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1952.72930340022010b"},{"key":"2025120618272657000_4.5.e004664.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60073-2"},{"key":"2025120618272657000_4.5.e004664.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339"},{"key":"2025120618272657000_4.5.e004664.11","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407826-0.00004-7"},{"key":"2025120618272657000_4.5.e004664.12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.V54.5.961.961","article-title":"Genetics of red cells and susceptibility to malaria","volume":"54","author":"Luzzatto","year":"1979","journal-title":"Blood"},{"key":"2025120618272657000_4.5.e004664.13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(79)91857-9","article-title":"The malaria\/G.-6-P.D. hypothesis","volume":"1","author":"Luzzatto","year":"1979","journal-title":"Lancet"},{"key":"2025120618272657000_4.5.e004664.14","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050253"},{"key":"2025120618272657000_4.5.e004664.15","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/blood.V84.11.3613.bloodjournal84113613","article-title":"G6PD deficiency","volume":"84","author":"Beutler","year":"1994","journal-title":"Blood"},{"key":"2025120618272657000_4.5.e004664.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040066"},{"key":"2025120618272657000_4.5.e004664.17","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.2009.953828"},{"key":"2025120618272657000_4.5.e004664.18","doi-asserted-by":"publisher","DOI":"10.1038\/hdy.2011.16"},{"key":"2025120618272657000_4.5.e004664.19","doi-asserted-by":"publisher","DOI":"10.1038\/190372a0"},{"key":"2025120618272657000_4.5.e004664.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00050-8"},{"key":"2025120618272657000_4.5.e004664.21","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-376"},{"key":"2025120618272657000_4.5.e004664.22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/beha.1999.0056","article-title":"Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants","volume":"13","author":"Fiorelli","year":"2000","journal-title":"Baillieres Best Pract Res Clin Haematol"},{"key":"2025120618272657000_4.5.e004664.23","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00051-10"},{"key":"2025120618272657000_4.5.e004664.24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008152.pub2"},{"key":"2025120618272657000_4.5.e004664.25","first-page":"601","article-title":"Malaria studies on the firestone rubber plantation in Liberia, West Africa","volume":"15","author":"Barber","year":"1932","journal-title":"Am J Hyg"},{"key":"2025120618272657000_4.5.e004664.26","first-page":"203","article-title":"Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika","volume":"27","author":"Clyde","year":"1962","journal-title":"Bull World Health Organ"},{"key":"2025120618272657000_4.5.e004664.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037166"},{"key":"2025120618272657000_4.5.e004664.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70198-6"},{"key":"2025120618272657000_4.5.e004664.29","unstructured":"WHO. World Malaria Report, 2011. Annex 3b. Country Antimalarial Drug Policies: By Region, 2010 . Geneva, Switzerland: World Health Organization, 2011."},{"key":"2025120618272657000_4.5.e004664.30","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-418"},{"key":"2025120618272657000_4.5.e004664.31","unstructured":"Recht J Ashley E White N . 8-aminoquinolines Safety Review for WHO Primaquine ERG. Unpublished 2012."},{"key":"2025120618272657000_4.5.e004664.32","first-page":"737","article-title":"Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology","volume":"21","author":"Bruce-Chwatt","year":"1959","journal-title":"Bull World Health Organ"},{"key":"2025120618272657000_4.5.e004664.33","unstructured":"WHO. Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation (October 2012). Geneva, Switzerland: Global Malaria Programme. World Health Organization, 2012. http:\/\/www.who.int\/malaria\/pq_updated_policy_recommendation_en_102012.pdf"},{"key":"2025120618272657000_4.5.e004664.34","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-360"},{"key":"2025120618272657000_4.5.e004664.35","unstructured":"Recht J Ashley E White N . Safety of 8-aminoquinolines: a review. Mahidol Oxford Research Unit, 2012."},{"key":"2025120618272657000_4.5.e004664.36","unstructured":"Uthman OA Graves P Gelban H . Safety of 8-aminoquinolones given to people with G6PD deficiency: systematic review of prospective studies. PROSPERO 2013;CRD42013006518. http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42013006518"},{"key":"2025120618272657000_4.5.e004664.37","unstructured":"Cochrane Effective Practice and Organisation of Care Group. Suggested risk of bias criteria for EPOC reviews. Secondary Suggested risk of bias criteria for EPOC reviews 2014. http:\/\/epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/uploads\/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf (accessed 14 Mar 2014)."},{"key":"2025120618272657000_4.5.e004664.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2025120618272657000_4.5.e004664.39","first-page":"601","article-title":"Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group","volume":"67","author":"WHO Working Group","year":"1989","journal-title":"Bull World Health Organ"},{"key":"2025120618272657000_4.5.e004664.40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1952.72930340027010c"},{"key":"2025120618272657000_4.5.e004664.41","first-page":"391","article-title":"Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug","volume":"59","author":"Clyde","year":"1981","journal-title":"Bull World Health Organ"},{"key":"2025120618272657000_4.5.e004664.42","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.75.402"},{"key":"2025120618272657000_4.5.e004664.43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178849"},{"key":"2025120618272657000_4.5.e004664.44","first-page":"720","article-title":"Effect of primaquine standard dose (15\u2005mg\/day for 14\u2005days) in the treatment of vivax malaria patients in Thailand","volume":"32","author":"Buchachart","year":"2001","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2025120618272657000_4.5.e004664.45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4269\/ajtmh.2007.77.779","article-title":"Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development","volume":"77","author":"Beutler","year":"2007","journal-title":"Am J Trop Med Hyg"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-004664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:27:36Z","timestamp":1765074456000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-004664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,14]]},"published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1136\/bmjopen-2013-004664"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-004664","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}